SEARCH:   Advanced

Blood, 1 April 2007, Vol. 109, No. 7, pp. 2700-2707. Prepublished online as a Blood First Edition Paper on November 21, 2006; DOI 10.1182/blood-2006-07-025809. This Article Full Text (PDF) All Versions of this Article: blood-2006-07-025809v1 109/7/2700    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jost, P. J. Articles by Ruland, J. Search for Related Content PubMed PubMed Citation Articles by Jost, P. J. Articles by Ruland, J. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 26, 2006 Accepted November 15, 2006 Aberrant NF-B signaling in lymphoma: mechanisms, consequences and therapeutic implications Philipp J. Jost and Jurgen Ruland* III. Medizinsche Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany * Corresponding author; email: jruland{at}lrz.tum.de. The transcription factor NF-B is a tightly regulated positive mediator of T and B cell development, proliferation and survival. The controlled activity of NF-B is required for the coordination of physiological immune responses. However, constitutive NF-B activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-B signaling in Hodgkin's disease and a variety of T and B cell non-Hodgkins lymphomas either upstream or downstream of the central IB kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF-B pathway and discusses the mechanisms of NF-B deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin's lymphoma (HL), diffuse large B cell lymphoma (DLBCL), MALT-lymphoma, primary effusion lymphoma (PEL) and adult T cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF-B signaling pathway as an attractive therapeutic target in T and B cell malignancies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Yan, J. Huang, N. R. Jarbadan, Y. Jiang, and H. Cheng Sequestration of NF-{kappa}B Signaling Complexes in Lipid Rafts Contributes to Repression of NF-{kappa}B in T Lymphocytes under Hyperthermia Stress J. Biol. Chem., May 2, 2008; 283(18): 12489 - 12500. [Abstract] [Full Text] [PDF] J. Ruland Signaling crosstalk in DLBCL Blood, April 1, 2008; 111(7): 3304 - 3304. [Full Text] [PDF] L. T. Lam, G. Wright, R. E. Davis, G. Lenz, P. Farinha, L. Dang, J. W. Chan, A. Rosenwald, R. D. Gascoyne, and L. M. Staudt Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma Blood, April 1, 2008; 111(7): 3701 - 3713. [Abstract] [Full Text] [PDF] S. V. Bradley, M. R. Smith, T. S. Hyun, P. C. Lucas, L. Li, D. Antonuk, I. Joshi, F. Jin, and T. S. Ross Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies Cancer Res., September 15, 2007; 67(18): 8923 - 8931. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020